Personalized Mapping of Drug Metabolism by the Human Gut Microbiome

1 s2.0 S0092867420305638 fx1Photo: © 2020 Elsevier Inc

The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine.

News source: Elsevier

Journal reference:

Bahar Javdan, Jaime G. Lopez, Pranatchareeya Chankhamjon, Ying-Chiang J. Lee, Raphaella Hull, Qihao Wu, Xiaojuan Wang, Seema Chatterjee, Mohamed S. Donia. Personalized Mapping of Drug Metabolism by the Human Gut Microbiome, Cell,

Targeting Microbiota 2021 Congress
October 20-22, 2021

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next